Search Results
Your search for this matches 25286 pages
Showing 7701 - 7750Newly Diagnosed Multiple Myeloma
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on...
Innovator in Treatment of Infectious Diseases, Francisco Marty, MD, Dies at 53
The Brigham and Women’s hospital community mourns the loss of Francisco Marty, MD, of the Division of Infectious Diseases, who died April 8, 2021, after a tragic accident while hiking in the Dominican Republic. He was 53. A member of the Brigham community for more than 20 years, Dr. Marty is...
OUTBACK: No Benefit for Adjuvant Chemotherapy in Cervical Cancer
In women with locally advanced cervical cancer, adjuvant chemotherapy adds no benefit to standard cisplatin-based chemoradiation, results of the international phase III OUTBACK study have shown,1 as reported at the 2021 ASCO Annual Meeting by Linda R. Mileshkin, MD, Professor of Medical Oncology at ...
Do Community Oncologists Have Access to Geriatric Specialty Care for Older Patients?
As our population rapidly ages, the burden of cancer incidence increases accordingly, creating an urgent need for greater and more incisive research on the diagnosis, treatment, and survivorship issues for older adults with cancer. Given the numerous challenges faced by today’s busy oncologists, a...
Expert Point of View: Rana R. McKay, MD
Invited discussant of the KEYNOTE-564 trial, Rana R. McKay, MD, Associate Professor of Medicine and Urology at the University of California San Diego, offered these comments about these trial results. “This is a positive study, showing a 32% reduction in the risk of recurrence or death with...
KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
Cancer in Morocco: Access to Innovative Treatments and Research Status
Morocco is an Arab country in North Africa. It covers 716,550 square kilometers and has a population of nearly 36 million. The median age is 29.3 years. Morocco’s estimated gross domestic product (GDP) in 2019 was $122 million. As of 2019, Morocco’s health budget was equivalent to 4.5% of the total ...
Whispers Over My Shoulder
When I interviewed for my current post as a first-time consultant in medical oncology in the United Kingdom, I was asked about my 5-year career plan. I remember some detail of my reply, but I don’t think it even remotely encompassed the depth of insight I would gain from the patients I’ve treated...
Expert Point of View: Mark G. Kris, MD, FASCO
Mark G. Kris, MD, FASCO, Chief of the Thoracic Oncology Service and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, New York, commented on the excitement in the field of lung cancer about the new drugs targeting KRAS. Sotorasib is one of several new...
Young Urologist of the Year Award Winners
Established by Michael C. Ost, MD, MBA, the 2012–2013 American Urological Association Young Urologists Committee Chair, the Young Urologist of the Year Award is presented annually to select early-career association members in recognition of their efforts and commitment to advancing the development...
AACR CEO Margaret Foti, PhD, MD (hc), to Receive Gallery of Success Award From Temple University
Margaret Foti, PhD, MD (hc), Chief Executive Officer (CEO) of the American Association for Cancer Research (AACR), has been selected as a Temple University Gallery of Success honoree for 2021. Each year, Temple University showcases exceptional alumni from its 17 schools and colleges in its Gallery...
Cynthia M. Yoshida, MD, Honored Nationally for Increasing Colorectal Cancer Screening Rates
Cynthia M. Yoshida, MD, is one of six winners of a national award recognizing health-care providers and institutions for their work to increase colorectal cancer screening rates. Dr. Yoshida, a gastroenterologist and medical leader of the University of Virginia (UVA) Cancer Center’s Colorectal...
Chanita Hughes-Halbert, PhD, to Advance Cancer Equity at USC Norris Comprehensive Cancer Center
Chanita Hughes-Halbert, PhD, will join the University of Southern California (USC) Norris Comprehensive Cancer Center as Associate Director for Cancer Equity, a newly created position, and the Keck School of Medicine of USC as Professor and Vice Chair of Research in the Department of Preventive...
Mary Daly, MD, PhD, FACP, Receives NCCN’s 2021 Rodger Winn Award
The National Comprehensive Cancer Network (NCCN) recently presented Mary B. Daly, MD, PhD, FACP, Professor in the Department of Clinical Genetics and Director of the Risk Assessment Program at Fox Chase Cancer Center, with the Rodger Winn Award. The Rodger Winn Award is given annually to one NCCN...
Harnessing a Worldwide Effort to Combat COVID-19 and Cancer
This past October, in a virtually held ceremony of the General Assembly of the Union for International Cancer Control (UICC), Anil K. D’Cruz, MBBS, MS, DNB, FRCS (Hon), Director of Oncology at Apollo Hospitals in Mumbai, Chennai, and Delhi, India, began his 2-year tenure as President of the global...
Sotorasib: Subgroup Analysis of Phase II Trial Shows Activity With Breakthrough KRAS Inhibitor in Lung Cancer
The breakthrough KRAS-specific inhibitor sotorasib achieved responses in patients with KRAS G12C–mutated non–small lung cancer (NSCLC) who had experienced disease progression on platinum-based chemotherapy, immunotherapy, or both treatments. The objective response rate was 37.1%, and responses...
How RAS Mutations in Early-Onset Colorectal Cancer May Impact Patient Survival
Although both incidence and mortality rates in colorectal cancer have been declining among people older than 65 by 3.3% and 3% annually, respectively, among individuals younger than age 50, the incidence rate has risen about 2% annually, and death rates have increased by 1.3% annually.1 Colorectal...
Expert Point of View: Nadine M. Tung, MD
Formal discussant of OlympiA, Nadine M. Tung, MD, Director of Breast Medical Oncology and the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center and Harvard Medical School, was enthusiastic about the ability of olaparib to improve invasive disease–free survival and...
Lessons From Pneumococcal Vaccine Responses in Patients With CLL in an Evolving Vaccine Landscape
The role of vaccines in mitigating the significant morbidity and mortality associated with infections in chronic lymphocytic leukemia (CLL) is a developing field of study, punctuated by the advent of novel therapeutic agents and pressing questions regarding the global SARS–CoV-2 vaccination...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
Expert Point of View: Sarah Blair, MD, FACS
Session moderator during the 2021 American Society of Breast Surgeons Annual Meeting, Sarah Blair, MD, FACS, Vice Chair of Academic Affairs for the Department of Surgery at University of California San Diego, urged widespread dissemination of these survey findings. “I was struck by how important...
Study Explores Taste and Smell Dysfunction in Head and Neck Cancer Survivors
Most survivors of head and neck squamous cell cancers report that their sense of taste is dulled, changed, or lost during radiation treatment. In a study of taste and smell dysfunction in 40 cancer survivors, scientists found that the tips of these individuals' tongues were significantly less...
Study Finds Patients With Bladder Cancer and Ureteric Obstruction May Safely Receive Chemotherapy
A study published by Strother et al in BJU International found that patients with muscle-invasive bladder cancer can safely receive cisplatin-based neoadjuvant chemotherapy, even when their tumors are blocking their kidneys. The findings suggest that patients with the most serious type of this...
Survival of Patients With Colon Cancer Enrolled in the U.S. Military Health System
A study by Lin et al comparing patients with colon cancer enrolled in the U.S. Military Health System, which provides universal health-care to its beneficiaries, with those in the general population has found that patients in the Military Health System had an 18% lower risk of death compared with...
Convalescent Plasma Therapy for Patients With Hematologic Cancers Hospitalized for COVID-19
In a retrospective cohort study reported in JAMA Oncology, Michael A. Thompson, MD, PhD, FASCO, and colleagues found that the use of convalescent plasma therapy was associated with improved 30-day mortality among patients with hematologic cancers hospitalized for COVID-19. Study Details The study...
FDA Pipeline: Priority Reviews in Multiple Myeloma, Cervical Cancer, Neutropenia, and Myelofibrosis
Over the past month, the U.S. Food and Drug Administration (FDA) has granted Priority Review to therapies for multiple myeloma, cervical cancer, chemotherapy-induced neutropenia, and myelofibrosis. The FDA also granted a number of Breakthrough Therapy designations, including those for treatments in ...
Overall Survival With the Addition of Ixazomib to Lenalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma
As reported in the Journal of Clinical Oncology by Paul G. Richardson, MD, and colleagues, the final overall survival analysis of the phase III TOURMALINE-MM1 trial showed no overall survival benefit with the addition of ixazomib to lenalidomide/dexamethasone (Rd) in relapsed or refractory multiple ...
Study Evaluates Residential Racial Segregation and NSCLC Treatment and Outcomes
Non–small cell lung cancer (NSCLC) accounts for 80% to 85% of cases of lung cancer; when it is diagnosed early, there is a 5-year survival rate of 50% to 80%. Black patients have a lower overall incidence of NSCLC than White patients but are more likely to be diagnosed at later stages. They also...
ASCO/Friends of Cancer Research Joint Position Statement Encourages Enrollment of Patients With Cancer in COVID-19 Vaccine Studies
Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, ASCO and Friends of Cancer Research (Friends) asserted in a joint position statement released today. To date, clinical trials...
Testing of Lymph Nodes for Breast Cancer Recurrence After Neoadjuvant Chemotherapy
A study published by Sharp et al in The Breast Journal suggests that some patients with breast cancer may be able to forgo certain testing procedures after neoadjuvant chemotherapy without increasing their risk of cancer recurrence. Prior studies on detecting whether breast cancer has spread to...
Study Explores Incidence Rates for Various Pediatric Cancers Across Age and Racial Groups
New research has uncovered substantial differences in the rates of childhood cancers when considering a single year of age rather than grouping several years together. The study, published by Marcotte et al in the journal Cancer, also found that minority children seem to have different risks than...
Addition of Isatuximab-irfc to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma: IKEMA Trial
As reported in The Lancet by Philippe Moreau, MD, and colleagues, the phase III IKEMA trial has shown that the addition of the anti-CD38 antibody isatuximab-irfc to carfilzomib and dexamethasone resulted in significantly improved progression-free survival in patients with relapsed or refractory...
Prevalence of Germline BRCA Mutations in Women With Ovarian Cancer in India
In a prospective cross-sectional study reported in JCO Global Oncology, Gupta et al found that women with ovarian cancer in India had a high prevalence of pathogenic or likely pathogenic BRCA variants. As stated by the investigators: “There are deficient data on prevalence of germline mutations in...
Lung Cancer Data From the 2021 ASCO Annual Meeting
On this episode, we’re looking specifically at data on lung cancer presented during the 2021 ASCO Annual Meeting.
Survivors of Early-Stage Breast Cancer Face Broad Range of Symptoms and Concerns
Patients with early-stage breast cancer may be at low risk of dying of their disease, but they experience a high burden of physical and psychological symptoms long after their treatment has ended, according to data presented during the 2021 American Society of Breast Surgeons Annual Meeting.1...
FDA Oncology Center of Excellence Launches National Black Family Cancer Awareness Week
The U.S. Food and Drug Administration (FDA)'s Oncology Center of Excellence (OCE) has announced its inaugural National Black Family Cancer Awareness Week, which is taking place from June 17 through June 23, 2021. Throughout the week, the agency’s social media platforms will serve as the hub for...
Retrospective Study Explores Variation in Colorectal Cancer Risk in Families With Lynch Syndrome
In a retrospective cohort study reported by Win et al in The Lancet Oncology, researchers in the International Mismatch Repair Consortium found marked variation in the risk of colorectal cancer in families with Lynch syndrome carrying the same pathogenic variant in DNA mismatch repair genes. The...
Expert Point of View: Anthony TC Chan, MD
The invited discussant of the JUPITER-02 study was Anthony TC Chan, MD, the Li Shu Fan Medical Foundation Professor of Clinical Oncology at Hong King Cancer Institute and Sir YK Pao Centre for Cancer at the Chinese University of Hong Kong. He noted that anti–PD-1/L1 therapies are at the forefront...
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer
A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial presented at the 2021 ASCO Annual Meeting by investigators from China.1 In the study, toripalimab, an anti–PD-1 monoclonal antibody, ...
Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL/SLL: ALPINE Trial
Zanubrutinib—a second-generation Bruton's tyrosine kinase (BTK) inhibitor—significantly improved response rates and delayed disease progression as compared to the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
Alkylating Signature in Colorectal Cancer May Be Linked to High Red Meat Intake
The association between the consumption of red and processed meats and the development of colorectal cancer, as well as pancreatic and prostate cancers, has been known since 2015, when the International Agency for Research on Cancer (IARC) classified the consumption of red meat as probably...
ASCO Releases Rapid Guideline Recommendation Update for Patients With High-Risk, HER2-Negative, Germline BRCA–Mutated Breast Cancer
A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk, early-stage, HER2-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations update the 2020...
De-escalating Surgery for Women With Breast Cancer
From routine axillary lymph node dissection to sentinel lymph node surgery, the use of axillary surgery continues to evolve in breast cancer. Recently, surgical oncologists have begun to consider avoiding axillary surgery completely in patients with a low risk of node-positive disease as well as in ...
Nearly Half of Surveyed Patients With Gynecologic Cancer Report Experiencing Financial Toxicity
In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...
Overall Survival Benefit With Upfront Daratumumab Plus Lenalidomide/Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
In an updated analysis of the phase III MAIA trial, the addition of daratumumab to lenalidomide and dexamethasone resulted in a statistically significant overall survival benefit over lenalidomide/dexamethasone alone in patients with newly diagnosed multiple myeloma who are ineligible for...
Adjuvant Platinum vs Capecitabine in Patients With Basal Subtype Triple-Negative Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy
As reported in the Journal of Clinical Oncology and during the 2021 ASCO Annual Meeting by Ingrid A. Mayer, MD, and colleagues, the phase III ECOG-ACRIN EA1131 trial investigated the use of adjuvant platinum vs capecitabine in patients with basal subtype triple-negative breast cancer and residual...
Computational Tool Suggests Optimal Treatment for Patients With High-Grade Ovarian Cancer
A mathematical tool may help to examine how doctors may coordinate available treatments for high-grade serous ovarian cancer. Published by Gu et al in the Proceedings of the National Academy of Sciences, the new analysis showed that patients who can have complete debulking surgery first, with...
Expert Point of View: Henry Kuerer, MD, PhD, FACS
Henry Kuerer, MD, PhD, FACS, a cancer surgeon and researcher at The University of Texas MD Anderson Cancer Center, told The ASCO Post that although this study is not practice-changing, it does offer a potential option for patients. “The advantage of this technique is that the procedure takes just...
Cryoablation in Low-Risk Breast Cancers: Minimally Invasive Procedure With Minimal Risk
Cryoablation is emerging as a new alternative to surgical excision for smaller early-stage, low-risk breast cancers in appropriately selected patient populations, according to data presented during the 2021 American Society of Breast Surgeons Annual Meeting.1 Early 3-year results of the multicenter ...
Expert Point of View: Mansoor Raza Mirza, MD
The invited discussant of EMPOWER-Cervical 1 was Mansoor Raza Mirza, MD, Chief Oncologist at Copenhagen University Hospital and Chairman of the European Network of Gynaecological Oncology Trials group (ENGOT). Dr. Mirza called the findings “amazing” and predicted they will “usher in a new era” in...
